Results 1 to 10 of about 14,789,856 (152)

Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis [PDF]

Nature Communications
Coagulation factor XII has been identified as a potential drug target that could prevent thrombosis without increasing the risk of bleeding. However, human data to support the development of factor XII-directed therapeutics are lacking.
Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven P. Grover, Pavan K. Bendapudi   +20 more
doaj   +3 more sources

Factor XII–driven coagulation traps bacterial infections [PDF]

Journal of Experimental Medicine
Factor XII drives thrombosis but is dispensable for hemostasis, making it an anticoagulant drug target. This study shows that factor XII–triggered coagulation traps pathogens and limits bacterial dissemination, highlighting a role of prothrombotic ...
Lynn M Butler, Praveen Papareddy, Mathias Gelderblom   +2 more
exaly   +3 more sources

Factor XII Structure-Function Relationships. [PDF]

Semin Thromb Hemost, 2023
Factor XII (FXII), the zymogen of the protease FXIIa, contributes to pathologic processes such as bradykinin-dependent angioedema and thrombosis through its capacity to convert the homologs prekallikrein and factor XI to the proteases plasma kallikrein ...
Shamanaev A, Litvak M, Ivanov I, Srivastava P, Sun MF, Dickeson SK, Kumar S, He TZ, Gailani D.   +8 more
europepmc   +2 more sources

Recent advances in factor XII structure and function. [PDF]

Curr Opin Hematol, 2022
Purpose of review Factor XII (FXII), the precursor of the protease FXIIa, contributes to pathologic processes including angioedema and thrombosis. Here, we review recent work on structure-function relationships for FXII based on studies using recombinant
Shamanaev A, Litvak M, Gailani D.
europepmc   +2 more sources

Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains. [PDF]

Blood Adv, 2022
Key Points The FXII EGF1 domain promotes surface binding, FXII activation on surfaces, and FXIIa activation of prekallikrein on surfaces. The FXII FN2 and KNG domains are part of a mechanism that restricts FXII activation in the absence of a surface.
Shamanaev A, Ivanov I, Sun MF, Litvak M, Srivastava P, Mohammed BM, Shaban R, Maddur A, Verhamme IM, McCarty OJT, Law RHP, Gailani D.   +11 more
europepmc   +2 more sources

Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.

Blood, 2023
A hypercoagulable state, chronic inflammation, and increased risk of venous thrombosis and stroke are prominent features in patients with sickle cell disease (SCD).
Sparkenbaugh EM, Henderson MW, Miller-Awe M, Abrams C, Ilich A, Trebak F, Ramadas N, Vital S, Bohinc D, Bane KL, Chen C, Patel M, Wallisch M, Renné T, Gruber A, Cooley B, Gailani D, Kasztan M, Vercellotti GM, Belcher JD, Gavins FE, Stavrou EX, Key NS, Pawlinski R.   +23 more
europepmc   +2 more sources

Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII-biointerface binding. [PDF]

Nat Mater
Antithrombotic surfaces that prevent coagulation activation without interfering with haemostasis are required for blood-contacting devices. Such materials would restrain device-induced thrombogenesis and decrease the need for anticoagulant use, thereby ...
Ji H, Yu K, Abbina S, Xu L, Xu T, Cheng S, Vappala S, Arefi SMA, Rana MM, Chafeeva I, Drayton M, Gonzalez K, Liu Y, Grecov D, Conway EM, Zhao W, Zhao C, Kizhakkedathu JN.   +17 more
europepmc   +2 more sources

A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation. [PDF]

Nat Commun
Factor XII (FXII) is the zymogen of the plasma protease FXIIa that activates the intrinsic coagulation pathway and the kallikrein kinin-system. The role of FXII in inflammation has been obscure.
Xu P, Zhang Y, Guo J, Li H, Konrath S, Zhou P, Cai L, Rao H, Chen H, Lin J, Cui Z, Ji B, Wang J, Li N, Liu DP, Renné T, Wang M.   +16 more
europepmc   +2 more sources

Cardiopulmonary bypass in a pediatric patient with factor XII deficiency [PDF]

The Journal of ExtraCorporeal Technology
The safe use of cardiopulmonary bypass (CPB) relies upon the ability to administer, monitor, and reverse anticoagulation. Although rare, the factor XII deficient patient creates a challenge for the perfusionist due to resultant complications in ...
Fenske Julie M., Tinius Juliani Julie, Herrington Cynthia   +2 more
doaj   +2 more sources

Roles of Factor XII in Innate Immunity

Frontiers in Immunology, 2019
Factor XII (FXII) is the zymogen of serine protease, factor XIIa (FXIIa). FXIIa enzymatic activities have been extensively studied and FXIIa inhibition is emerging as a promising target to treat or prevent thrombosis without creating a hemostatic defect.
Thomas Renné, Evi X. Stavrou, Evi X. Stavrou   +2 more
doaj   +2 more sources